Collegium CEO Michael Heffernan Named EY Entrepreneur of the Year

CANTON, Mass., June 27, 2016 (GLOBE NEWSWIRE) -- EY announced that Collegium’s CEO, Michael Heffernan, received the EY Entrepreneur of the Year® 2016 Award in the Life Sciences and Healthcare category in New England. This year marks the 30th anniversary of the EY Entrepreneur of the Year Award program. The award recognizes outstanding entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance, and personal commitment to their businesses and communities. Winners were selected by an independent panel of judges, and the award was presented at a special gala event at the Marriott Copley Place on June 23, 2016.

“On behalf of Collegium’s Board of Directors, I’d like to congratulate Mike on receiving this well-deserved honor,” said Gino Santini, Director of Collegium. “Mike’s extraordinary leadership and entrepreneurial spirit are instrumental to Collegium’s past and future success.”

“I’d like to thank my colleagues from Collegium who have worked tirelessly for many years to address two major epidemics in the United States: chronic pain and prescription opioid abuse. The development and launch of Xtampza^™ ER is a tribute to their dedication and commitment to providing solutions for these devastating problems,” said Michael Heffernan, CEO of Collegium.

As a New England award winner, Mike Heffernan is now eligible for consideration for the Entrepreneur of the Year 2016 national program. Award winners in several national categories, as well as the Entrepreneur of the Year National Overall Award winner, will be announced at the Entrepreneur of the Year National Awards gala in Palm Springs, California, on November 19, 2016.

About EY Entrepreneur of the Year

EY Entrepreneur of the Year is the world’s most prestigious business award for entrepreneurs. The unique award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, Entrepreneur of the Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities in more than 60 countries.

About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx^® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

About Xtampza ER

Xtampza ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

For Important Safety Information Visit, http://www.xtampzaer.com/

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: our ability to commercialize our products and product candidates; the existence of any patent infringement or similar litigation relating to any of our products or product candidates, and costs and delays associated with such litigation; the size and growth potential of the markets for our product and product candidates, and our ability to service those markets; our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of our product and product candidates; the success, cost and timing of our product development activities, studies and clinical trials; the success of competing products that are or become available; and our expectations regarding our ability to obtain and adequately maintain sufficient intellectual property protection for our product candidates. These and other risks are described under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2015, and those risks described from time to time in other reports which we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.